Human immortalized parathyroid fibroblast cell line pthcaf-x2 and uses thereof

By constructing the PTHcaf-X2 cell line, the problem of the lack of human immortalized parathyroid fibroblast cell lines in existing technologies has been solved, providing a stable and controllable research tool and promoting the progress of parathyroid disease research.

CN123063353APending Publication Date: 2026-11-10THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611529663.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-30
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

There are currently no publicly reported human immortalized parathyroid fibroblast cell lines, which restricts the advancement of basic and clinical translational research on parathyroid diseases. There is an urgent need to construct stable and reliable human immortalized parathyroid fibroblast cell lines to provide research models.

Method used

Parathyroid tissue obtained from patients who underwent parathyroidectomy was digested with type II dispersase and type IV collagenase and then cultured in primary culture. Immortality was achieved by infection with SV40T lentivirus. Monoclonal culture was performed using the limiting dilution method, and a human immortalized parathyroid fibroblast cell line named PTHcaf-X2 was screened and expanded.

Benefits of technology

The constructed PTHcaf-X2 cell line exhibits stable traits, controllable proliferation, and a clear lineage, which can effectively promote the development of basic research and clinical diagnosis and treatment technologies for parathyroid diseases, and provide a reliable cell model for drug screening and mechanism research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063353A_ABST
    Figure CN123063353A_ABST
Patent Text Reader

Abstract

The immortalized human parathyroid fibroblast cell line PTHcaf-X2 and its applications belong to the field of microbial and animal cell line technology. The aforementioned immortalized human parathyroid fibroblast cell line (PTHcaf-X2) homo sapiens The cell line, named PTHcaf-X2, has the accession number CCTCC NO: C2026197. It was constructed using a combination of primary parathyroid fibroblast culture and SV40T lentivirus infection for immortalization. The immortalized human parathyroid fibroblast cell line PTHcaf-X2 is used in the preparation, screening, or evaluation of parathyroid therapeutic drugs. It is also used as a parathyroid cell model and as experimental material in basic or clinical research on parathyroid glands.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of microbial and animal cell line technology, specifically relating to a human immortalized parathyroid fibroblast cell line PTHcaf-X2 and its applications. Background Technology

[0002] The parathyroid glands are important endocrine organs that regulate calcium homeostasis by releasing parathyroid hormone (PTH). Abnormal parathyroid function can lead to excessive or insufficient PTH secretion, causing primary or secondary hyperparathyroidism, hypoparathyroidism, and other diseases, thereby disrupting calcium homeostasis and leading to various clinical manifestations. Currently, treatment for parathyroid diseases has limited effectiveness, and patients' quality of life is significantly lower than that of healthy individuals.

[0003] Fibroblasts, as crucial components of the parathyroid stromal microenvironment, interact closely with parathyroid chief cells. Human immortalized parathyroid fibroblast lines serve as a bridge between basic research and clinical applications, playing an irreplaceable role, particularly in drug screening and mechanism studies. Their application value will be further expanded in the future with the development of organoid and 3D culture technologies.

[0004] Currently, there are no publicly reported human immortalized parathyroid fibroblast cell line models, which greatly restricts the advancement of basic research and clinical translational research on parathyroid diseases. There is an urgent need to construct a stable and reliable human immortalized parathyroid fibroblast cell line to provide cell model support for research in this field. Summary of the Invention

[0005] The purpose of this invention is to address the current situation regarding the lack of human immortalized parathyroid fibroblast cell lines by providing the human immortalized parathyroid fibroblast cell line PTHcaf-X2 and its applications, thus providing a research model for parathyroid medical research.

[0006] To achieve the above objectives, the present invention adopts the following technical solution:

[0007] This invention provides a human immortalized parathyroid fibroblast cell line, named human immortalized parathyroid fibroblast cell line PTHcaf-X2. homo sapiens The cell line was deposited on September 1, 2026, at the China Center for Type Culture Collection (CCTCC), located at Wuhan University, Wuhan, China, with accession number CCTCC NO: C2026197.

[0008] Cell line establishment: Parathyroid tissue obtained from a patient who underwent parathyroidectomy was digested with a mixture of type II dispersase and type IV collagenase and then cultured in primary culture. The primary parathyroid fibroblasts were immortalized using standard cell culture techniques and SV40T lentivirus infection. The immortalized cells were then cultured as monoclonal cells using the limiting dilution method. After the selected monoclonal cell lines were expanded, an immortalized parathyroid fibroblast cell line was successfully constructed and named PTHcaf-X2.

[0009] This person's immortalized parathyroid fibroblast cell line PTHcaf-X2 homo sapiens It has the following biological characteristics:

[0010] 1. Cell growth characteristics: The cells adhere to the wall and are mainly elongated spindle-shaped or irregular star-shaped, which is consistent with the typical morphological characteristics of fibroblasts.

[0011] 2. Cell doubling time: 19.4 h.

[0012] 3. Cell origin traceability characteristics: The cells were confirmed to be novel human cell lines by short tandem repeat (STR) sequence detection, with no cross-contamination from existing cell lines.

[0013] 4. Cell typing characteristics: Immunohistochemical results showed that PTHcaf-X2 cells are fibroblast cell lines.

[0014] 5. Immortality characteristics: PTHcaf-X2 cells acquired immortality ability after infection with SV40T lentivirus, and were able to transcribe SV40T mRNA and translate SV40T protein.

[0015] The immortalized human parathyroid fibroblast cell line PTHcaf-X2 can be used as a cell model for drug screening and mechanism research.

[0016] The immortalized human parathyroid fibroblast cell line PTHcaf-X2 can be used in the preparation, screening, or evaluation of parathyroid therapeutic drugs;

[0017] The immortalized human parathyroid fibroblast cell line PTHcaf-X2 can be used as a parathyroid cell model.

[0018] The immortalized human parathyroid fibroblast cell line PTHcaf-X2 can be used as an experimental material in basic or clinical research on parathyroid glands.

[0019] Application of the human immortalized parathyroid fibroblast cell line PTHcaf-X2 in the study of the physiological and pathological mechanisms of parathyroid glands.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] This invention constructs a novel human immortalized parathyroid fibroblast cell line, PTHcaf-X2, providing a new tool for the study of parathyroid diseases. This cell line is stable, has controllable proliferation, and a clear origin, providing a new and irreplaceable research tool for the study of the mechanisms of parathyroid diseases, drug development, and clinical translation. It can effectively promote the development of basic research and clinical diagnosis and treatment technology for parathyroid diseases, and has extremely high scientific research value and industrial application prospects. Attached Figure Description

[0022] Figure 1 Morphological observation of PTHcaf-X2 cells under a 100x microscope.

[0023] Figure 2 Morphological observation of PTHcaf-X2 cells under a 200x microscope.

[0024] Figure 3 The results are shown in the immunohistochemical images of PTHcaf-X2 cells. In the images, A indicates positive expression of Vimentin in cells; B indicates weak positive expression of α-SMA in cells; C indicates negative expression of CT in cells; and D indicates negative expression of CKpan in cells.

[0025] Figure 4 This is a comparison of the relative expression levels of SV40T mRNA between PTHcaf-X2 cells and primary parathyroid fibroblasts.

[0026] Figure 5 Images shown are indirect immunofluorescence images of PTHcaf-X2 cells and primary parathyroid fibroblasts. In the images, A is a DAPI staining image of PTHcaf-X2 cell nuclei, B is an immunofluorescence staining image of PTHcaf-X2 cells for SV40T protein, C is a DAPI staining image of primary parathyroid fibroblast nuclei, and D is an immunofluorescence staining image of primary parathyroid fibroblasts for SV40T protein.

[0027] Figure 6 The graph shows the proliferation curve of PTHcaf-X2 cells. The x-axis represents cell culture time, and the y-axis represents cell number. Detailed Implementation

[0028] To make the objectives, technical solutions, and advantages of this invention clearer, the following embodiments will be used in conjunction with the accompanying drawings to further illustrate the invention. It should be understood that the specific embodiments described herein are for illustrative purposes only and are not intended to limit the invention. Rather, this invention covers any substitutions, modifications, equivalent methods, and solutions made within the spirit and scope of the invention as defined by the claims. Unless otherwise specified, the experimental methods described in the following embodiments are conventional methods.

[0029] I. Establishment of the human immortalized parathyroid fibroblast cell line PTHcaf-X2

[0030] This invention utilizes parathyroid tissue samples surgically removed from a clinically diagnosed female patient who underwent parathyroidectomy. Under aseptic conditions, the parathyroid tissue was thoroughly removed, and adhering fat, connective tissue, and vascular impurities were eliminated. The tissue samples were then subjected to isothermal digestion with a mixed enzyme solution of type II dispersant enzyme and type IV collagenase, followed by primary culture. Once the primary cells reached the logarithmic growth phase, the simian vacuolating virus 40 large T antigen (SV40T) gene was introduced into the primary cells using lentiviral infection. A preliminary immortalized cell population was screened using puromycin, and then the selected immortalized cells were cultured as monoclonal cells using a limiting dilution method. Monoclonal cell lines with uniform morphology and stable growth were selected. After multiple generations of expanded culture and stability acclimation, a stable immortalized parathyroid fibroblast cell line was successfully constructed and named PTHcaf-X2. This cell line was deposited on September 1, 2026, at the China Center for Type Culture Collection (CCTCC, located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan, Hubei Province, China), with accession number CCTCC NO:C2026197.

[0031] II. Detection of biological characteristics of the human immortalized parathyroid fibroblast cell line PTHcaf-X2

[0032] 1. Cell morphology observation

[0033] After the cells stabilized and were passaged, live cell observation was performed. Morphological observation of PTHcaf-X2 cells under a microscope is shown below. Figure 1 and Figure 2 As shown. Among them, Figure 1 Cell morphology under a 100x microscope. Figure 2 Cell morphology under a 200x microscope. Results showed that PTHcaf-X2 cells were arranged in a fibroblast-like pattern under the microscope. The cells adhered to the wall and were mainly long spindle-shaped or irregular star-shaped. There were no atypical cells or contaminating cells, which is consistent with the typical morphological characteristics of human fibroblasts, confirming that the constructed cells are fibroblast-like cells.

[0034] 2. Immunohistochemical staining

[0035] PTHcaf-X2 cells in logarithmic growth phase were trypsinized and seeded onto sterile glass slides for growth. After 24 h, the culture medium was removed, the slides were washed three times with PBS, fixed with 4% paraformaldehyde solution for 15 min, and then permeabilized with 0.5% Triton X-100 solution for 20 min. The slides were incubated with BSA solution at room temperature for 20–30 min to reduce non-specific antibody binding. Then, the slides were incubated with anti-Vimentin, anti-α-SMA, anti-CT, and anti-CKpan at 37°C for 2 h, respectively. After washing three times with PBS, secondary antibodies were added and incubated at 37°C for 1 h. DAB staining was performed using a kit, and the slides were mounted with neutral resin and observed under a microscope. The results are shown below. Figure 3 As shown. Figure 3 The A in the text indicates that Vimentin is positively expressed in the cell, and the staining site is located in the cytoplasm; Figure 3 In this context, B indicates weak positive expression of α-SMA in cells; Figure 3 The "C" in the text indicates that CT (calcitonin) is negatively expressed in cells; Figure 3 The "D" in the figure indicates that CKpan is negatively expressed in the cells. The expression profile of the above markers perfectly matches the typing characteristics of parathyroid fibroblasts, confirming that PTHcaf-X2 cells are a parathyroid fibroblast cell line.

[0036] 3. Identification of SV40T gene expression in cells

[0037] Total RNA was extracted from primary parathyroid fibroblasts and 15th generation PTHcaf-X2 cells, and the RNA was reverse transcribed into cDNA. The mRNA expression level of the SV40T target gene in primary and PTHcaf-X2 cells was detected using real-time quantitative polymerase chain reaction (RT-qPCR), with GAPDH as an internal control. Primer sequences are shown in the sequence listing (Seq ID NO:1–Seq ID NO:4).

[0038] Table 1 Primer sequences for the target gene

[0039]

[0040] Note: SV40T: Simian vacuolating virus 40 large T antigen; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase.

[0041] Real-time quantitative qPCR was performed using a Mastercycler Nexus GSX1 gradient PCR system (Eppendorf, Germany) with TB Green dye as the detection method. The qPCR reaction system consisted of 100 ng of DNA template and 2× TB Green dye. Premix Ex Taq II. Fast qPCR: 12.5 μL of 10 μmol / L upstream primer, 1 μL of 10 μmol / L downstream primer, and sterile water to a final volume of 25 μL per tube. Reaction conditions were as follows: pre-denaturation at 95℃ for 3 min, denaturation at 95℃ for 10 s, annealing at 60℃ for 30 s, for a total of 40 cycles. The method was used for relative quantitative analysis, and the results are as follows: Figure 4 As shown. Compared with primary parathyroid fibroblasts, the mRNA expression level of SV40T in PTHcaf-X2 cells was significantly increased (as shown). P The result of <0.0001 indicates that the SV40T gene is integrated into PTHcaf-X2 cells and can be transcribed into mRNA, which proves the success of cell immortalization at the gene level.

[0042] 4. Indirect immunofluorescence identification

[0043] Primary parathyroid fibroblasts in logarithmic growth phase and PTHcaf-X2 cells (passage 25) were seeded in 12-well plates and cultured. Once the cells reached a monolayer, the culture medium was discarded, and the cells were washed three times with PBS. They were then fixed with 4% paraformaldehyde at 4°C for 30 min, followed by the addition of 0.5 mL of 0.25% Triton X-100 permeabilizer and incubated at room temperature for 10 min. The cells were then washed three times with PBS containing 1% BSA. After incubation at room temperature for 2 h with mouse anti-SV40T monoclonal antibody (mAb), the cells were washed three times with PBS containing 1% BSA. Each well was then incubated with 1:50 diluted Alexa Fluor® 488-labeled goat anti-mouse IgG antibody and a final concentration of 5 μg / mL DAPI solution, and incubated in the dark at room temperature for 2 h. The cells were washed three times with PBS containing 1% BSA, and 0.5 mL of PBS was added to each well. The cells were observed and photographed under a fluorescence microscope. The results are shown below. Figure 5 As shown. It can be seen that the nuclei of PTHcaf-X2 cells were stained with DAPI ( Figure 5 A in the sample is blue and has been stained with SV40T antibody ( Figure 5 B) showed green fluorescence (positive expression of SV40T protein); while primary cells showed only blue fluorescence in the nucleus after DAPI staining. Figure 5 In the C), primary cells SV40T staining showed no green fluorescence (C). Figure 5The presence of negative expression of SV40T protein in the D-cells demonstrates that PTHcaf-X2 cells stably express SV40T protein, while the primary parathyroid fibroblast control group, which has not undergone lentiviral modification, does not express SV40T protein. This fully verifies at the protein level that the immortalization modification of the PTHcaf-X2 cell line constructed in this invention was successful and that its immortalization characteristics are stable.

[0044] 5. STR testing

[0045] PTHcaf-X2 cells in logarithmic growth phase were collected and sent to Suzhou Jianda Biotechnology Co., Ltd. for STR analysis. The STR results are shown in Table 2, confirming that the PTHcaf-X2 cell line was not cross-contaminated with cells in the existing cell line database, and that PTHcaf-X2 is a novel human cell line.

[0046] Table 2. Overview of PTHcaf-X2 cell STRs

[0047]

[0048] In Table 2, loci with only a single value represent those loci as homozygous.

[0049] 6. Determination of cell doubling time

[0050] PTHcaf-X2 cells in the logarithmic growth phase were selected, and single-cell suspensions were prepared and counted. 0 and 2.5 × 10⁻⁶ cells were respectively... 3 4×10 3 7.5×10 3 1×10 4 1.25×10 4 1.5×10 4 1.75×10 4 and 2×10 4 Cells were seeded per well in 96-well plates, with 6 replicates per group. The plates were incubated at 37°C in a 5% CO2 incubator. After cell attachment, 110 μL of CCK8 working solution (RPMI-1640:CCK8 = 10:1) was added per well. After incubation for 2 h, the absorbance of each well was measured at 450 nm. A standard curve was plotted with cell number on the x-axis and OD value on the y-axis.

[0051] 7.5×10 3Cells were seeded in 96-well plates with a blank control. At 0, 24, 48, 72, 96, and 120 h, 110 μL / well of CCK8 working solution was added. After incubation for 2 h, the absorbance of each well was measured at 450 nm. Growth curves of PTHcaf-X2 cells were plotted using GraphPad Prism 8.0.2, with seeding time on the x-axis and cell number on the y-axis, and the cell doubling time was calculated. The doubling time of PTHcaf-X2 cells was approximately 19.4 h. The proliferation curve of PTHcaf-X2 cells is shown below. Figure 6 As shown. Figure 6 It clearly shows the growth trend of cells at different time points, providing intuitive data support for a deeper understanding of cell proliferation characteristics.

[0052] This invention constructs an immortalized human fibroblast monoclonal cell line derived from parathyroid tissue. This cell line possesses complete biological characteristics, has been confirmed by STR testing to be a novel human cell line, exhibits no cross-contamination with existing cell lines, and can be stably passaged over a long period. It can be used for research related to the parathyroid microenvironment, providing a new in vitro cell model for elucidating the mechanisms of parathyroid diseases, drug screening and development, and clinical translational research.

[0053] The above embodiments are merely preferred embodiments of the present invention and should not be considered as limiting the scope of the present invention. All equivalent variations and improvements made within the scope of the present invention should still fall within the patent coverage of the present invention.

Claims

1. The human immortalized parathyroid fibroblast cell line PTHcaf-X2, characterized in that... This cell line was constructed by immortalizing human parathyroid fibroblasts derived from human parathyroid tissue using SV40T lentivirus, and was named the human immortalized parathyroid fibroblast cell line PTHcaf-X2. homo sapiens It was deposited at the China Center for Type Culture Collection on September 1, 2026, with accession number CCTCC NO: C2026197.

2. The application of the human immortalized parathyroid fibroblast line PTHcaf-X2 as described in claim 1 as a parathyroid cell model.

3. The use of the human immortalized parathyroid fibroblast cell line PTHcaf-X2 as described in claim 1 in the preparation, screening, or evaluation of parathyroid therapeutic drugs.

4. The application of the human immortalized parathyroid fibroblast cell line PTHcaf-X2 as described in claim 1 as an experimental material in basic research, clinical research, and in vitro research on the physiological or pathological mechanisms of the parathyroid gland.